Medical Center Veterans Affairs

CURRICULUM VITAE

William H. Arnold, Jr.

Address and Telephone Numbers

**** ** **

Minden, NE 68959

402-***-**** (cell)

e-mail: *********@*****.***

Personal Information

Birth Date: July 25, 1961

Place of Birth: Kearney, Nebraska

Children: Leslie 1981, Nicholas 1983, Shelby 1991

Citizenship USA

Licensure/Certificates

State of Nebraska

Pharmacist License, 12343

LPN License number, 10253 expired

First Responder

Citi Web-based Training in Protection of Human Research Subjects

Dangerous Goods Training and Certification

Asthma: Managing & Marketing a Specialty Service

OSHA 30 hour Certificatio

Education

1980 First Respond Central Community College

Kearney, Nebraska

1981-1982 LPN Central Community College School of Practical Nursing

Kearney, Nebraska

1987-1991 B.S., Biology University of Nebraska at Omaha

Omaha, Nebraska

95.95.M.A., Biology University of Nebraska at Omaha

Omaha, Nebraska

2001-2005 PharmD School of Pharmacy and Allied Health Professions, Creighton University

Omaha, Nebraska

2011- MDiv program Sioux Falls Seminary, Sioux Falls, SD, Omaha, Nebraska campus

Doctor of Pharmacy Clerkships

Hospital Management: Veterans Affairs Medical Center, Omaha, Nebraska

Preceptor: Thomas Zorn, RP

Community Pharmacy: Target Stores, Omaha, Nebraska

Preceptor: Lee Miltner, RP

Adult Acute Care: Veterans Affairs Medical Center, Omaha, Nebraska

Preceptor: Keith Christensen, Pharm. D.

Ambulatory Care: Veterans Affairs Medical Center, Omaha, Nebraska

Preceptor: Steven Boyd, Pharm. D.

Drug Information: Children's Hospital, Omaha, Nebraska

Preceptor: Kathryn Bartels, Pharm. D.

Critical Care: Veterans Affairs Medical Center, Omaha, Nebraska

Preceptor: Keith Christensen, Pharm. D.

Infectious Diseases: Creighton University Medical Center, Omaha, Nebraska

Preceptor: Christopher DeStache, Pharm. D.

Long Term Care: Quality Living Inc., Omaha, Nebraska

Preceptor: Ann Ryan-Haddad, Pharm. D.

Employment

86.86.LPN 2nd-3rd Shift Supervisor

Bethphage Mission, Axtell, Nebraska

86.86.Psychiatric Technician

Douglas County Hospital, Omaha, Nebraska

91-98 LPN Oncology Unit

VA Medical Center, Omaha, Nebraska

98-01 Laboratory Health Technician

VA Medical Center, Omaha, Nebraska

94.94.Graduate Teaching Assistant

University of Nebraska at Omaha, Omaha, Nebraska

01-05Study Coordinator

Creighton University/VA Medical Center, Omaha, Nebraska

2001.2001. Instructor

Omaha College of Health Careers, Omaha, Nebraska

2003-2004 Pharmacy Intern

Keystone/Medicine Chest, Omaha, Nebraska

2003-2005 Pharmacy Intern

Target Pharmacy, Omaha, Nebraska

2005-2007 Clinical Pharmacist-Home Infusion

FirstChoice HealthCare/InfuScience, Omaha, Nebraska

2007-2008 Pharmacist in Charge

Omaha Treatment Center, Omaha, Nebraska

2006-2022 Clinical Pharmacist

Methodist Health Systems/Midwest Surgical Hospital, Omaha, Nebraska

Lead Pharmacist Midwest Surgical Hospital, Omaha, Nebraska

PIC retail pharmacy at MSH.

2008-2024 Pharmacist in Charge

Biomed/Soleo health, Omaha, NE

2008-2010 Pharmacist e-focus, eICU/VISICU

Relief Pharmacist, Lakeside/Immanuel Hospital

Alegent Health Care, Omaha, Nebraska

2022- Walgreens Clinical Pharmacist

Consultant

Cohen Vacanti Higgins Shattuck Attorneys at Law 2005-2009

Biomed Pharmaceuticals/SoleoHealth, PIC 2008-

Omaha Surgical Hospital 2010-2011

Awards and Honors

American Red Cross Service Pin 1982

Administrators' Award Excellence in Nursing 1991

Omicron Delta Kappa National Leadership Society 1991

Nebraska State Scholarship 1987-1991

Alan J. Blotcky Memorial Science Scholarship 2001-2004

Creighton University, Dean's List 2002-2005

Brett G. Sherman Memorial Endowed Scholarship 2004

Student Government Leadership Award 2004

Harry and Fay Lane Pharmacy Scholarship 2005

US Public Health Service Award 2005

Professional Activities

Bethphage Mission, Axtell, Nebraska

Safety Committee 1982-1986

Central Community College, School of Nursing, Kearney, Nebraska

Class president 1981-1982

American Red Cross

Blood Pressure clinics 1981-1986

CPR Instructor 1981-1991

Coordinator, Emergency Services 1982-1983

Speakers Bureau 1991-1992

Kearney State College

Secretary/Treasurer Kearney State Soccer Club 1984-1985

University of Nebraska at Omaha

Graduate Student Representative Graduate Program Committee 1994-1995

Student Health Advisory Council 1990-1991

Omicron Delta Kappa 1991-

Licensed Practical Nurses Association of Nebraska

President, Kearney Unit 1983-1984

President Division 4 1984-1985

Delegate National Convention, Chicago IL 1985

Creighton University

Class President, School of Pharmacy and Allied Health Professions Class of 2005 2003- 2004

Midwest Surgical Hospital (Methodist Affiliate) 2008-

Pharmacy and Therapeutics Committee

Infection Control Committee

Safety Committee

Quality Assurance Committee

Presentations

1.Arnold WH, and Weber AT. A Macrocyst-Specific Surface Component of Dictyostelium mucoroides Identified by a Monoclonal Antibody. ASM Missouri Valley Branch Annual Meeting, Omaha, Nebraska. March 8-9, 1996

2.Use of a Monoclonal Antibody to analyze Surface Proteins of Dictyostelium mucoroides during Development. Nebraska Academy of Sciences, Lincoln, Nebraska. April, 1995.

3.Atrial Fibrillation. Veterans Affairs Medical Center, Omaha, Nebraska. September, 2004.

4.Aspiration Pneumonia. Veterans Affairs Medical Center, Omaha, Nebraska. September, 2004.

5.Animal Bites. Creighton University Medical Center, Omaha, Nebraska. March, 2005.

6.Aspiration Pneumonia vs. COPD. Creighton University Medical Center, March, 2005.

7.Allergies. Quality Living Incorporated. Omaha, Nebraska, April 2005.

Articles

1.Bittner MJ, Rich EC, Turner PD, Arnold Jr., WH. Limited impact on handwashing frequency in an adult intensive care unit of sustained simple feedback based on soap and paper towel consumption. Infect Control Hosp Epidemiol 2002;23:120-126.

2.Bittner MJ, Rich EC, Turner PD, Arnold Jr., WH, Lubeley MW. Impact on handwashing frequency of nursing workload and winter season in adult intensive care units. Submitted to Am J Infect Control

3.Stout, JE, Muder, RR, Arnold, Jr., WH, et al. Role of Environmental Surveillance in Determining the Risk of Hospital-Acquired Legionellosis: A National Surveillance Study with Clinical Correlations. Infect Control Hosp Epidemiol 2007;28:818-824.

Abstracts and Other Brief Communications

1.Use of a Monoclonal Antibody to Analyze Surface Proteins of Dictyostelium mucoroides during Macrocyst Development. International Dictyostelium Conference. San Diego, California. August 1994.

2.A Macrocyst-Specific Surface Component of Dictyostelium mucoroides Identified by a Monoclonoal Antibody (Poster). ASM, New Orleans, Louisiana, May 1996.

8.Effectiveness of Simple Feedback on Handwashing in Adult Intensive Care Units (Poster). University of Nebraska Medical Center, Omaha, Nebraska, July 1998.

9.Transient improvement in handwashing frequency in an adult intensive care unit associated with sustained simple feedback based on soap and towel consumption. Scientific Presentation (Poster S15), April 18, 1999. 9th Annual Meeting of the Society for Healthcare Epidemiology of America, San Francisco, California, April 18-20, 1999.

10.Impact on handwashing frequency of nursing workload and winter season in adult intensive care units. Abstract submitted to 4th Decennial International Conference on Nosocomial and Healthcare Associated Infections, Atlanta, Georgia, March 5-9, 2000.

11.Review of Quinolone Antibiotic Use at Creighton University Medical Center. Scientific Presentation (Poster #31), October 16, 2003 American College of Physicians Nebraska Chapter Scientific Meeting, Omaha, Nebraska, October 16-17, 2003.

12.Endemic Legionellosis Uncovered in a Prospective Study of Hospital-acquired Legionnaires' Disease: Value of Environmental Monitoring. Scientific Presentation (Poster) APIC Meeting, Phoenix, AZ, June 4, 2004.

CURRENT RESEARCH ACTIVITIES

NONE ACTIVE

Grants submitted

1.Bittner MJ (PI), Rich EC (PI), Arnold WH Jr. (Research Assistant). Evaluation of handwashing improvement to reduce nosocomial infections. Central Plains Network VISN 14 Health Services Research/Clinical Outcomes Research Program. Submitted 10/1/97. 1 yr. $30,000.

2.Bittner MJ (PI), Rich EC (mentor), Holleman DR Jr. (mentor), Arnold WH Jr (Research Assistant). Evaluation of handwashing improvement to reduce nosocomial infections. VA HSR&D Career Development Program. Letter of Intent submitted 11/1/97. LOI #98-335.1 approved 12/17/97. Full proposal submitted 2/15/98. 3 yr. $146,890.

3.Bittner MJ (PI), Rich EC (co-investigator), Arnold WH Jr. (Research Assistant). Influence of house staff experience and work load on patient outcomes. American Legion of Iowa Foundation. Submitted 4/8/99. 6 mo. $8,246.25.

4.Bittner MJ (PI), Rich EC (co-investigator), Arnold WH Jr. (Research Assistant). Protecting patients: Effectiveness of hand disinfection interventions. VA HSR&D Investigator Initiated Research. LOI #IIR-20037-1 approved 3/27/00. Full proposal submitted11/1/00. 3 yr. $281,731.

5.Bittner, MJ (PI), Arnold WH Jr. (Research Assistant) Legionella colonization of health facility water systems. American Legion of Iowa Foundation. Submitted 3/28/01. 1 yr. $4,000.

6.Bittner MJ (PI), Rich EC (Co-I), Arnold WH Jr. (Research Assistant). The effectiveness of hand disinfection with alcohol gel in protecting patients. Health Future Foundation. Submitted 4/16/01. 2 yr. $20,000.

7.Bittner, MJ (PI), Arnold WH Jr. (Research Assistant). Hand disinfection interventions to protect patients. Creighton University, State of Nebraska LB 692 Tobacco Settlement Funds. Submitted 7/5/01. 2 yr. $180,000.

8.Bittner MJ (PI), Arnold WH Jr. (Research Assistant) Legionella colonization of health facility water systems. American Legion of Iowa Foundation. Submitted 4/5/02. 1 yr. $4,000.

PREVIOUS RESEARCH ACTIVITIES

1.Evaluation of handwashing improvement to reduce nosocomial infections. Principal Investigator. Co-investigator: Eugene C. Rich, M.D, Research Assistant William H. Arnold, Jr. VA #05. [IRB approval 10/86. Data collection 11/19/97 - 8/18/00.]

Expanded access programs

1.Open study of Synercid. (Quinupristin/Dalfopristin, RP 59500) for emergency use (infections due to resistant bacteria, treatment failure or in treatment-intolerant patients). Protocol Number JRV 397. VA #44. Rhone-Poulenc Rorer. [IRB approval 8/20/97.]

2.A randomized open-label expanded access program to evaluate the safety of Preveon (adefovir dipivoxil) at two dose levels when used in combination with other antiretroviral agents for the treatment of patients with HIV infection who have limited treatment options. Protocol GS-97-423. VA #57. Gilead Sciences. [IRB approval 8/19/98.]

3.Amprenavir (141W94) open label protocol for subjects with HIV-1infection who have experienced treatment failure or are intolerant to previous protease inhibitor therapy. Protocol PRO30010. VA #60. Glaxo Wellcome. [IRB approval 11/18/98.]

4.A multicenter, randomized study to compare the safety and efficacy of levofloxacin with that of imipenem-cilastatin sodium followed by ciprofloxacin hydrochloride in the treatment of complicated skin and skin structure infections in hospitalized patients. Phase III. Protocol L91-038. VA #26. R.W. Johnson Pharmaceutical Research Institute. [IRB approval 12/8/93. Enrollment 2/15/94-10/24/94.]

5.Comparative cost effectiveness study of clarithromycin, erythromycin stearate and cefaclor in the treatment of lower respiratory tract infections. Protocol M94-184. VA #27. Abbott Laboratories. PACT. [IRB approval 9/9/94. Enrollment 1/2/95-2/23/96.]

6.A randomized, multicenter, investigator-blind trial comparing intravenous CP-116,517 followed by oral CP-99,219 with intravenous ciprofloxacin and ampicillin followed by oral ciprofloxacin and amoxicillin for the treatment of community acquired pneumonia. Protocol 154-110. VA #28. Pfizer Inc. Pharmaco LSR. [IRB approval 11/16/94. Enrollment 1/20/95-2/28/96.]

7.A randomized, double-blind, multicenter trial comparing 7 days of oral therapy with CP-99,219 (100 mg daily) and clarithromycin (500 mg bid) for the treatment of acute exacerbation of chronic bronchitis. Protocol 154-109. VA #29. Pfizer Inc. Pharmaco LSR. [IRB approval 2/95. No enrollment.]

8.An open-label, randomized, comparative, multicenter study of clinafloxacin versus a ceftazidime-based regimen in the treatment of nosocomial pneumonia. Protocol 960-012-35. VA #30. Parke-Davis Pharmaceutical Research. [IRB approval 8/15/95. Enrollment 4/27/96-9/25/96.]

9.Randomized placebo-controlled trial of MAK 195F in sepsis with hyperinflammatory response. Protocol MAK 195F 009. VA #31. Knoll Pharmaceutical Company. IBAH Bio-Pharm & The Hardardt Group. [IRB approval 9/19/95. Enrollment 5/3/96-10/28/98.]

10.Comparative study of cefpodoxime proxetil (Vantin® tablets) vs. clarithromycin (Biaxin® tablets) in the treatment of acute bacterial exacerbation of chronic bronchitis in smokers. Protocol M/1140/0118. VA #32. The Upjohn Company. [IRB approval 11/18/95. Enrollment 1/17/96-5/17/98.]

11.A randomized, multicentre, double-blind, double-dummy trial comparing CP-99,219 with amoxicillin and optional erythromycin for the treatment of community acquired pneumonia. Protocol 154-112. VA #33. Pfizer Inc. Pharmaco LSR. [IRB approval 12/12/95. Enrollment 3/14/96-4/30/96.]

12.MSI-78 topical cream vs. oral ofloxacin in the treatment of infected diabetic foot ulcers. Protocol #MSI-78-304. VA #35. Magainin. [IRB approval 3/18/96. No enrollment.]

13.A multicenter randomized comparative trial with ampicillin/sulbactam plus oral azithromycin or ampicillin/sulbactam plus intravenous erythromycin in the treatment of moderately ill hospitalized subjects with community-acquired pneumonia. Protocol # R-0440. VA #36. Pfizer Inc. [IRB approval 3/20/96. Enrollment 6/14/96-11/4/96.]

14.A randomized, multicentre trial comparing two blinded dose levels of CP-99,219 (100 mg & 200 mg) with open amoxicillin/clavulanate ("Augmentin" 500/125 mg tid) for the treatment of acute exacerbation of chronic obstructive bronchitis. Protocol 154-135. VA #37. Pfizer Inc. Pharmaco LSR. [IRB approval 5/10/96. No enrollment.]

15.A double-blind, prospective, randomized, multicenter comparative study of clinafloxacin vs. a ceftriaxone-based regimen in the treatment of hospitalized patients with community-acquired pneumonia. Protocol No.960-033-02. VA #38. Parke-Davis Pharmaceutical Research [IRB approval 5/10/96. Enrollment 3/20/97-3/19/98.]

16.An investigator-blind, randomized, comparative, multicenter study of clinafloxacin vs. piperacillin/ tazobactam in the treatment of complicated skin and soft tissue infections. Protocol 960-015-30. VA #39. Parke-Davis Pharmaceutical Research. [IRB Approval 7/15/96. No enrollment.]

17.A comparative study of the efficacy and safety of clarithromycin extended release tablets and cefixime tablets for the treatment of patients with acute bronchitis. Protocol Number M96-456. VA #40. Abbott Laboratories. Covance/Corning PACT. [IRB approval 12/96. Protocol not initiated for technical reasons.]

18.A randomized, multicenter, third party blinded trial comparing trovafloxacin with amoxicillin/clavulanate (Augmentin®) with or without erythromycin for the treatment of community acquired pneumonia. Protocol Number R-0520. VA #42. Pfizer Inc. PPD Pharmaco. [IRB Approval 2/19/97. Enrollment 5/29/97-12/23/97.]

19.Antithrombin III in patients with severe sepsis: A multinational, double-blind, randomized, placebo-controlled Phase III study. Protocol BI51.017/7M N-303SE. VA #43. Centeon. PPD Pharmaco. [IRB approval 2/19/97. No enrollment.]

20.Open study of Synercid® (Quinupristin/Dalfopristin, RP 59500) for emergency use (infections due to resistant bacteria, treatment failure or in treatment-intolerant patients). Protocol Number JRV 397. VA #44. Rhône-Poulenc Rorer. [IRB approval 8/20/97. Enrollment 2/5/98.]

21.A multicenter, randomized, open-label study to compare the safety and efficacy of iv and/or oral levofloxacin with that of ticarcillin/clavulanate alone or followed by amoxicillin/clavulanate in the treatment of complicated bacterial skin and skin structure infections. Protocol LOFBIV-SSS-040. VA #46. R.W. Johnson Pharmaceutical Research Institute. Advanced Biologics. [IRB Approval 10/22/97. Enrollment 6/22/98-6/26/98.]

22.A multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin vs. azithromycin in the treatment of moderate to severe community-acquired pneumonia in adults. Protocol CAPSS-056. VA #47. R.W. Johnson Pharmaceutical Research Institute. Advanced Biologics. [IRB approval 10/22/97. Enrollment 4/2/98-5/23/99.]

23.An open label, multicenter, rollover study of the safety of saquinavir soft gelatin capsules in combination with other antiretroviral agents in HIV-infected patients. Protocol NV 15651. VA #48. Hoffmann-La Roche. [IRB approval 11/19/97. Enrollment 10/23/97.]

24.Open-label comparative, randomized, multicenter phase III study of intravenous treatment of Synercid® 7.5 mg/kg q 8 hours plus aztreonam 2 g q 8 hours versus either vancomycin 1 g q 12 hours plus aztreonam 2 g q 8 hours, or imipenem 0.5 g q 6 hours in the treatment of 190 adult evaluable hospitalized patients with nosocomial pneumonia due, at least in part, to Gram positive cocci. Protocol RP 59500V-311. VA #49. Rhône-Poulenc Rorer. PPD Pharmaco. ICON Clinical Research. [IRB approval 12/10/97. Enrollment open 7/15/99- ]

25.Comparative safety and efficacy of cefditoren pivoxil and Augmentin® (Amoxicillin/Clavulanate potassium) in the treatment of acute maxillary sinusitis. Protocol CEF-97-004. VA #50. TAP Holdings. [IRB approval 1/9/98. No enrollment.]

26.A comparative study of the efficacy of clarithromycin and azithromycin for the treatment of patients with acute exacerbation of chronic bronchitis. Protocol M/97-766. VA #51. Abbott Laboratories. Covance. [IRB approval 1/9/98. No enrollment.]

27.International quality of life survey in community-acquired pneumonia. Protocol 48-7435. VA #52. Bayer Pharmaceutical Research. [IRB approval 4/10/98. No enrollment.]

28.Sustiva™ (efavirenz) expanded access program. Protocol DMP 266-903. VA #53. The DuPont Merck Pharmaceutical Company. [IRB approval 3/13/98. Enrollment 5/15/98-8/19/98.]

29.Linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections: An evaluator-blinded trial comparing linezolid with vancomycin alone and vancomycin followed by oral linezolid. Protocol M/1260/0031. VA #55. Pharmacia & Upjohn. [IRB approval 6/5/98. No enrollment.]

30.Comparative safety and efficacy of cefditoren pivoxil and cefuroxime axetil in the treatment of patients with uncomplicated skin or skin structure infection. Protocol CEF-97-009. VA #56. TAP Holdings Inc. [IRB approval 6/5/98. No enrollment.]

31.A randomized open-label expanded access program to evaluate the safety of Preveonä (adefovir dipivoxil) at two dose levels when used in combination with other antiretroviral agents for the treatment of patients with HIV infection who have limited treatment options. Protocol GS-97-423. VA #57. Gilead Sciences. [IRB approval 8/19/98. No enrollment.]

32.A double-blind, multicenter, randomized, active-controlled, two-arm parallel-group comparative study of the efficacy and safety of oral HMR 3647 (800 mg once daily) versus oral clarithromycin (500 mg twice daily) in the treatment of community-acquired pneumonia in adults. Protocol HMR3647A/3006. VA #58. Hoechst Marion Roussel. [IRB approval 10/21/98. No enrollment.]

33.A 1592U89 [abacavir] open label protocol for adult patients with HIV-1 infection, part B. Protocol CNAA 3008. VA #59. Glaxo Wellcome. [IRB approval 10/21/98. No enrollment.]

34.LY333328 vs. vancomycin in skin/skin-structure infections. Protocol H4Q-MC-ARRD(a) . VA #61. Eli Lilly and Company. [IRB approval 11/18/98.]

35.Prospective, randomized, double-blind, multicenter comparison of safety and efficacy of sequential (IV to PO) BAY 12-8039 400/400 mg QD for 7-14 days versus sequential Trovan™ I.V./Trovan™ Tablets 200/200 mg QD for 7-14 days (initial phase) and of sequential (IV to PO) BAY 12-8039 400/400 mg QD for 7-14 days versus sequential Levaquin® injection/Levaquin® Tablets 500/500 mg QD for 7-14 days in the treatment of patients with community acquired pneumonia. Protocol 100039. VA#62 Bayer. [IRB approval 12/4/98. Enrollment 11/8/99-]

36.A randomised open multicentre study to compare the efficacy, safety and tolerability of oral gemifloxacin versus intravenous ceftriaxone (with or without macrolide) followed by oral cefuroxime (with or without macrolide) in the treatment of hospitalized adult patients with community-acquired pneumonia (CAP). Protocol 265805/185. VA #64. SmithKline Beecham. [IRB review 11/4/99.]

37.Is it the flu? Canaris G, Nichol D, Wigton R, Tape T, Flach S, Bittner M, Investigators. VA #65. [IRB 8/15/00. Enrollment 1/21/01-2/20/01.]

38.Model text material as a way to improve consent form readability. Bittner MJ, Rotella JA, Brennan JM. VA #66. [IRB approval 8/16/00.]

39.An open label, non-comparative study to assess the efficacy and safety of oral gemifloxacin 320 mg, once daily for seven days, for the treatment of community-acquired pneumonia of suspected pneumococcal origin in countries with a high prevalence of drug-resistant pathogens. Protocol SB-265805/287. VA #67. SmithKline Beecham. [IRB approval 9/7/00. Enrollment 3/19/01-1/24/02.]

40.A multicenter, open-label, non-comparative study to evaluate the safety and efficacy of levofloxacin 750 mg once a daily for five days in the treatment of mild to severe community-acquired pneumonia in adults. Protocol CAPSS-171. VA #68. Ortho-McNeil. [IRB approval 12/8/00.]

41.A multicenter, double-blind, randomized study to compare the safety and efficacy of levofloxacin 750 mg once daily for 5 days vs. levofloxacin 500 mg once daily for 10 days in the treatment of mild to severe community-acquired pneumonia in adults. Protocol CAPSS-150. VA #69. Ortho-McNeil. [IRB approval 12/8/00.]

42.A multicenter, randomized, double-blinded comparison of the safety and efficacy of GAR-936 with those of Vancomycin/Aztreonam to treat complicated skin and skin structure infections in hospitalized patients. Protocol 3074A1-300-US. VA #71. Wyeth-Ayerst. [IRB approval 6/12/01.]

43.Legionella colonization of health facility water systems. Participating Investigator. Robert Muder, Principal Investigator. VA #70. [IRB approval 3/21/01 and 9/26/01. Enrollment 11/20/01-9/1/02 and continuing.]

44.An open-label, randomized, study comparing the efficacy and safety of piperacillin/tazobactam and ampicillin/sulbactam administered intravenously in the empirical treatment of foot infections in diabetic inpatients. Protocol 0910X-100468-US. VA #72. Wyeth-Ayerst. [IRB approval 7/17/01.]

45.Sitostanol-ester margarine vs. canola margarine in patients on statins. With Roger Riedell, co-investigator. VA #73. [IRB approval 3/19/02.]Supplemental data collection for veterans with HIV/AIDS. VA #74. [IRB approval 7/23/02.]

46.A case study of the development of VISN 23. VA #78. [IRB approval 12/5/02

47.VISN 23 integration scorecard. VA #79. [IRB approval 12/5/02.

48.A multicenter, randomized, double-blind comparison of the safety and efficacy of tigecycline with those of vancomycin with aztreonam to treat complicated skin and skin structure infections in hospitalized patients. Protocol #3074A1-300-US. VA #75. Wyeth.

49.A study of Avelox for treatment of elderly patients with community acquired pneumonia (The SAFE CAP Study). Protocol 10872. VA #76. Bayer. [IRB approval 10/15/02]

50.A prospective observational study of acute major organ system failure in septic patients. Protocol EMD20003. VA #77. GlaxoSmithKline. [IRB approval 12/19/02]

51.Efficacy and safety of drotrecogin alfa (activated) in adult patients with early stage severe sepsis. Protocol F1K-MC-EVCL. VA #80. Eli Lilly and Company.

52.The influence of house staff experience and work load on patient outcomes. Co-Principal Investigator with Eugene C. Rich, M.D., Research Assistant William H. Arnold, Jr. VA #54. Department of Veterans Affairs, Central Plains Network VISN 14 Health Services Research/Clinical Outcomes Research Program. Data collection 7/1/98-6/30/99.

53.Amprenavir (141W94) open label protocol for subjects with HIV-1 infection who have experienced treatment failure or are intolerant to previous protease inhibitor therapy. Protocol PRO30010. VA #60. Glaxo Wellcome. [IRB approval 11/18/98. Enrollment 12/8/98-1/26/99.]

Contact this candidate